Skip to main content

Together we are beating cancer

Donate now

Cancer News

For Researchers

Showing 12 out of 391 results

We answer questions from the research community about our refreshed Research Strategy We answer questions from the research community about our refreshed Research Strategy

by Phil Prime | Interview | 29 March 2022

29 March 2022

The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research. The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.

by Phil Prime | Podcast | 23 March 2022

23 March 2022

This entry is part 2 of 9 in the series Cancer Research Matters - series 1
%postcontent%

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials... Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials...

by Cancer Research UK | In depth | 18 March 2022

18 March 2022

  • Science & Technology
  • Health & Medicine
  • For Researchers

Why diversity in STEM is vital to cancer research

Cancer Research UK has an important role in fostering a diverse and inclusive research environment, and here we give a brief summary of our response to the consultation and explain why this matters for cancer research… Cancer Research UK has an important role in fostering a diverse and inclusive research environment, and here we give a brief summary of our response to the consultation and explain why this matters for cancer research…

by Cancer Research UK | Analysis | 3 March 2022

3 March 2022

This entry is part 4 of 10 in the series Diversity in research
%postcontent%
Seb
  • For Researchers
  • Science & Technology

Embracing a full spectrum of researchers

For drug discovery scientist Sebastian Greenhough, a late diagnosis of autism made sense of several things – but something it certainly didn’t do was stand in the way of his research For drug discovery scientist Sebastian Greenhough, a late diagnosis of autism made sense of several things – but something it certainly didn’t do was stand in the way of his research

by Cancer Research UK | Analysis | 24 February 2022

24 February 2022

This entry is part 5 of 10 in the series Diversity in research
%postcontent%
Vivian Li, group leader of the stem cell and cancer biology lab at the Francis Crick Institute

Disrupted cell signalling, hijacked stem cells and the power of 'mini-guts' – we hear from Dr Vivian Li on the challenges and opportunities of developing colorectal cancer treatments. Disrupted cell signalling, hijacked stem cells and the power of 'mini-guts' – we hear from Dr Vivian Li on the challenges and opportunities of developing colorectal cancer treatments.

by Phil Prime | In depth | 11 February 2022

11 February 2022

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 9 in the series Cancer Research Matters - series 1
%postcontent%

Chief clinician Charlie Swanton gives some of his personal reflections on how far research has come and why sustained investment is so important for the therapies of the future. Chief clinician Charlie Swanton gives some of his personal reflections on how far research has come and why sustained investment is so important for the therapies of the future.

by Charles Swanton | Analysis | 4 February 2022

4 February 2022

Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach. Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach.

by Cancer Research UK | Analysis | 4 February 2022

4 February 2022

  • For Researchers
  • Science & Technology

Seven Centres to form new Cancer Research UK network

From 1 April, we’re investing £100 million over five years into seven Cancer Research UK Centres across the UK. From 1 April, we’re investing £100 million over five years into seven Cancer Research UK Centres across the UK.

by Cancer Research UK | In depth | 24 January 2022

24 January 2022

Two of our Research Committee Chairs take stock of the incredible science done over 2021 and tell us what they are excited about in the year to come Two of our Research Committee Chairs take stock of the incredible science done over 2021 and tell us what they are excited about in the year to come

by Phil Prime | Analysis | 21 January 2022

21 January 2022

Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers... Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers...

by Phil Prime | In depth | 13 December 2021

13 December 2021